1
|
Georgantzi K, Tsolakis AV, Stridsberg M, Jakobson A, Christofferson R, Janson ET. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer 2011; 56:584-9. [PMID: 21298743 DOI: 10.1002/pbc.22913] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2010] [Accepted: 10/15/2010] [Indexed: 02/02/2023]
Abstract
BACKGROUND Neuroblastoma (NB) is a solid tumor of childhood originating from the adrenal medulla or sympathetic nervous system. Somatostatin (SS) is an important regulator of neural and neuroendocrine function, its actions being mediated through five specific membrane receptors. The aim of this study was to investigate the expression of the different somatostatin receptors (SSTRs) in NB tumor cells that may form targets for future therapeutic development. PROCEDURE Tumor specimens from 11 children with stage II-IV disease were collected before and/or after chemotherapy. Experimental tumors derived from five human NB cell lines were grown subcutaneously in nude mice. Expression of SSRTs, the neuroendocrine marker chromogranin A (CgA) and SS was detected by immunohistochemistry using specific antibodies. RESULTS SSTR2 was detected in 90%, SSTR5 in 79%, SSTR1 in 74%, SSTR3 in 68% whereas SSTR4 was expressed in 21% of the clinical tumors. The experimental tumors expressed SSTRs in a high but variable frequency. All clinical tumors showed immunoreactivity for CgA but not for SS. CONCLUSION The frequent expression of SSTRs indicates that treatment with unlabeled or radiolabeled SS analogs should be further explored in NB.
Collapse
Affiliation(s)
- Kleopatra Georgantzi
- Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
| | | | | | | | | | | |
Collapse
|
2
|
Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors. J Clin Oncol 2008; 26:963-70. [DOI: 10.1200/jco.2007.12.7431] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Purpose Well-differentiated metastatic endocrine carcinomas are difficult to manage because of variable disease outcome. New prognostic factors are required. These tumors overexpress somatostatin receptors (sst), implying the use of somatostatin analogs for tumor localization by somatostatin receptor scintigraphy using indium-111–pentetreotide (111In-pentetreotide) and for medical treatment. The aim of the present study was to evaluate the correlation between 111In-pentetreotide scintigraphy, sst receptor expression, and prognosis. Patients and Methods Between 1994 and 2002, 48 consecutive patients with well-differentiated endocrine carcinomas and a negative 111In-pentetreotide scintigraphy were retrospectively paired according to sex, age, and tumor localization with 50 patients with well-differentiated endocrine carcinomas and a positive tracer uptake at 111In-pentetreotide scintigraphy. Overall survival and expression of sst1 to sst5 receptors by immunohistochemistry were assessed. Results The lack of tracer uptake at the 111In-pentetreotide scintigraphy seemed to be a poor prognostic factor (P = .007) for overall survival by Kaplan-Meier test and in multivariate analysis; age and absence of clinical secretory syndrome also seemed to be poor prognostic factors. The tracer uptake (positive 111In-pentetreotide scintigraphy) correlated with the tumor expression of somatostatin receptor sst2 (P < .001) but not with that of sst1, sst3, sst4, or sst5. In a bivariate analysis, lack of sst2 expression also significantly correlated with poor prognosis. Conclusion We demonstrate the prognostic value of 111In-pentetreotide scintigraphy in well-differentiated malignant endocrine tumors. In these tumors, sst2 somatostatin receptor expression correlates with both tracer uptake and a better prognosis.
Collapse
Affiliation(s)
- Amani Asnacios
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Frédéric Courbon
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Philippe Rochaix
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Eric Bauvin
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Valérie Cances-Lauwers
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Christiane Susini
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Stefan Schulz
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Andrée Boneu
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Rosine Guimbaud
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| | - Louis Buscail
- From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany
| |
Collapse
|
3
|
Berger A, Santic R, Hauser-Kronberger C, Schilling FH, Kogner P, Ratschek M, Gamper A, Jones N, Sperl W, Kofler B. Galanin and galanin receptors in human cancers. Neuropeptides 2005; 39:353-9. [PMID: 15944034 DOI: 10.1016/j.npep.2004.12.016] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2004] [Accepted: 12/08/2004] [Indexed: 02/02/2023]
Abstract
The increasing interest in peptides and peptide receptors in cancer is based on the possibility of receptor targeting, because peptide receptors are often expressed in different human tumors. The neuropeptide galanin has also been suggested to be involved in the development of neuroendocrine tumors based on the development of estrogen-induced tumors in estrogen-sensitive rats. This study summarizes our current knowledge on the expression of galanin peptide and galanin receptors in different human neuroendocrine tumors. The expression of both, peptide and corresponding receptor, seems to be a common feature of human gliomas, pheochromocytomas, pituitary and neuroblastic tumors. The co-expression of galanin and its receptors supports a role for galanin in tumor cell pathology via autocrine/paracrine mechanisms.
Collapse
Affiliation(s)
- Alexandra Berger
- Department of Pediatrics, Paracelsus Private Medical University, Salzburg, Muellner-Hauptstrasse 48, A-5020 Salzburg, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Thomas RP, Hellmich MR, Townsend CM, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003; 24:571-99. [PMID: 14570743 DOI: 10.1210/er.2002-0028] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Gastrointestinal (GI) hormones are chemical messengers that regulate the physiological functions of the intestine and pancreas, including secretion, motility, absorption, and digestion. In addition to these well-defined physiological effects, GI hormones can stimulate proliferation of the nonneoplastic intestinal mucosa and pancreas. Furthermore, in an analogous fashion to breast and prostate cancer, certain GI cancers possess receptors for GI hormones; growth can be altered by administration of these hormones or by blocking their respective receptors. The GI hormones that affect proliferation, either stimulatory or inhibitory, include gastrin, cholecystokinin, gastrin-releasing peptide, neurotensin, peptide YY, glucagon-like peptide-2, and somatostatin. The effects of these peptides on normal and neoplastic GI tissues will be described. Also, future perspectives and potential therapeutic implications will be discussed.
Collapse
Affiliation(s)
- Robert P Thomas
- Department of Surgery, The University of Texas Medical Branch, Galveston, Texas 77555, USA
| | | | | | | |
Collapse
|